Atezolizumab Combo Improves PFS in MSI-H mCRC

Key Takeaways

• In previously untreated dMMR/MSI-H metastatic colorectal cancer, first-line atezolizumab plus modified FOLFOX6 and bevacizumab was associated with longer progression-free survival than atezolizumab alone.
• The combination regimen produced an objective response rate of 86% versus 46% with atezolizumab alone.
• Complete responses occurred in 36% versus 19%, and primary disease progression was markedly reduced with the combination regimen.
• dMMR/MSI-H disease accounts for about 5% of metastatic colorectal cancers, and about one-third of patients have primary resistance or early progression on single-agent immunotherapy.

Deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer often responds to immunotherapy, yet early resistance or progression still leaves an open first-line treatment question for a meaningful share of patients. That gap has focused attention on whether adding cytotoxic therapy and vascular endothelial growth factor blockade to checkpoint inhibition can deepen disease control in a biomarker-defined population already considered immunotherapy sensitive. The unresolved question in this setting was whether atezolizumab combined with modified FOLFOX6 and bevacizumab could improve outcomes beyond atezolizumab alone.

The COMMIT randomized study in the Journal of Clinical Oncology, identified as NRG-GI004/SWOG S1610, was a randomized first-line comparison in previously untreated dMMR/MSI-H metastatic colorectal cancer. Patients were assigned to atezolizumab plus modified FOLFOX6 chemotherapy and bevacizumab or to atezolizumab alone.

Published efficacy findings from the Journal of Clinical Oncology publication of COMMIT showed a 58% reduction in the risk of disease progression or death with the combination versus atezolizumab alone. The reported hazard ratio was 0.42, and median progression-free survival was 24.5 months with atezolizumab plus modified FOLFOX6 and bevacizumab and 5.3 months with atezolizumab alone. These findings favored the combination regimen for progression-free survival.

Tumor response also favored the multidrug approach, with an objective response rate of 86% in the combination arm and 46% with atezolizumab alone. Complete response rates were 36% and 19%, respectively. Primary disease progression was also markedly reduced with the combination regimen.

Clinician Questions

What treatments were compared in the COMMIT trial for first-line dMMR/MSI-H metastatic colorectal cancer?

COMMIT, also identified as NRG-GI004/SWOG S1610, randomized patients with previously untreated dMMR/MSI-H metastatic colorectal cancer to atezolizumab alone or to atezolizumab plus modified FOLFOX6 chemotherapy and bevacizumab.

What was the progression-free survival result with atezolizumab plus mFOLFOX6 and bevacizumab in dMMR/MSI-H metastatic colorectal cancer?

In previously untreated dMMR/MSI-H metastatic colorectal cancer, atezolizumab plus modified FOLFOX6 and bevacizumab was associated with a 58% reduction in the risk of progression or death versus atezolizumab alone, with a hazard ratio of 0.42 and median progression-free survival of 24.5 months versus 5.3 months.

How did response rates differ between COMMIT treatment arms in previously untreated dMMR/MSI-H metastatic colorectal cancer?

In previously untreated dMMR/MSI-H metastatic colorectal cancer, objective response rate was 86% with atezolizumab plus modified FOLFOX6 and bevacizumab versus 46% with atezolizumab alone, and complete responses were 36% versus 19%, while primary disease progression was described as markedly reduced with the combination.

Why was combination therapy tested in dMMR/MSI-H metastatic colorectal cancer despite immunotherapy sensitivity?

dMMR/MSI-H tumors account for about 5% of metastatic colorectal cancers, and about one-third of patients with dMMR/MSI-H metastatic colorectal cancer experience primary resistance or early progression on single-agent immunotherapy, prompting evaluation of adding chemotherapy and bevacizumab to atezolizumab.